© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
<<<